Clinical trials represent an important step in the development of new therapeutic proteins.

At ZymoGenetics, we are advancing a number of product candidates into clinical development, led by rThrombin (as an aid to controlling bleeding in surgeries), atacicept (for autoimmune diseases and B-cell malignancies), IL-21 (for cancer) and PEG-interferon lambda (for hepatitis C).

As new clinical trials open, we will post information about each one.